ArticlemedRxiv : the preprint server for health sciences2026
Integrating 730,947 exome sequences with clinical literature improves gene discovery.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
55 authors.
Funding
Abstract
Accurate estimates of allele frequencies aid in genetic discovery, including rare disease diagnosis, common disease investigations, and population genetics. Here, we present the Genome Aggregation Database version 4 (gnomAD v4), including 730,947 with exome sequences, a fivefold increase over previous releases. We demonstrate that statistical power to detect strong selective constraint continues to increase with sample size. We develop a new loss-of-function annotation pipeline, which learns genomic features predictive of nonsense-mediated decay and splicing effects from selection signals, achieving 90% precision for distinguishing likely true versus false positive loss-of-function variants. This improved pipeline, along with incorporation of highly deleterious missense variants into measures of loss-of-function intolerance, improves disease gene detection, particularly for short genes and those with gain-of-function mechanisms. To improve disease gene prediction, we systematically extract gene-disease associations from biomedical literature, map these to gene-level biological features, and integrate both with refined constraint metrics within a Bayesian framework, yielding state-of-the-art prediction of gene-disease relevance. We highlight genes under strong constraint but with limited clinical characterization, which are enriched in embryonic lethal and fertility phenotypes, thus prioritizing previously under-characterized disease genes. Together, these advances establish a unified framework for accelerating gene discovery and improving rare disease diagnosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.